FUS mRNA — Drug Target

All drugs that target FUS mRNA — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Antisense oligonucleotide

Phase 3 pipeline (1)

• GTX-102 · Ultragenyx Pharmaceutical Inc · Antisense oligonucleotide · Neurology
  GTX-102 is an antisense oligonucleotide that reduces production of FUS protein by targeting FUS mRNA in patients with FUS-associated neurological disease.